Article Text

PDF
AB0660 Predictors of Flare after Tapering Anti-TNF Therapy in Patients with Axial Spondyloarthritis
  1. I. Monjo Henry,
  2. C. Plasencia,
  3. V. Navarro-Compán,
  4. B. Paredes,
  5. G. Bonilla,
  6. L. Nuño,
  7. D. Peiteado,
  8. A. Villalba,
  9. D. Pascual-Salcedo,
  10. S. Ramiro,
  11. E. de Miguel,
  12. E. Martín-Mola,
  13. A. Balsa
  1. University Hospital La Paz, IdiPaz, Madrid, Spain

Abstract

Background In most patients with axial spondyloarthritis (axSpA) achieving a clinical response after receiving standard dose of anti-TNF therapy, it seems possible to decrease anti-TNF dose without leading to flare of the disease. However, a minority of patients fails to this strategy and need to maintain standard dose of anti-TNF therapy in order to keep disease activity under control.

Objectives To identify prognostic factors of flare after tapering anti-TNF therapy in patients with axSpA who achieve sustained clinical response with standard dose of this therapy.

Methods This was a restrospective, observational study performed in a tertiary hospital. All patients with axSpA who had achieved sustained low disease activity for at least 6 months after receiving standard dose of a first anti-TNF drug and who had later decreased the dose of anti-TNF therapy were included. Low disease activity was defined as BASDAI <4 plus normal value of CRP. All patients were followed-up during 2 years after starting on tapering strategy. Collected data included: demographic (age, gender) and disease characteristics (HLA-B27, disease duration, peripheral involvement), smoking status, clinical disease activity measures (BASDAI, ASDAS, CRP) before starting and before decreasing anti-TNF therapy, time under anti-TNF therapy, concomitant treatment, and time in remission before tapering. Patients were followed-up during 2 years after tapering anti-TNF therapy. Flare was defined as BASDAI ≥4 plus elevated CRP (>5mg/L) and/or delta-BASDAI ≥2. To identify possible predictors of flare, univariable and multivariable logistic regression analyses were employed including all variables described within the collected data as independent factors.

Results Fifty-three patients with axSpA receiving a tapering strategy after achieving low disease activity were included. Characteristics for these patients are presented in table 1. Four patients interrupted anti-TNF due to adverse effect before ending the study. In total, 8/49 patients (16%) had a flare during the 2-year follow-up period. In the univaribale analysis, only the age (OR=1.06; p=0.05), BASDAI before tapering (OR=2.64; p=0.01) and ASDAS before tapering (OR=4.12; p=0.08) were significantly associated with the occurrence of flare. In the multivariable analysis, only the BASDAI before tapering remained statistically significantly associated with flare (OR=2.39; p=0.03).

Conclusions In patients with axSpA and sustained clinical response to anti-TNF therapy, a tapering strategy leads to flare in less than 20% of patients. The value of BASDAI before tapering anti-TNF therapy predicts the occurrence of flare. This may help us to select the appropriate patients and moment to implement a tapering strategy in patients with axSpA.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.